Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: The objective of this randomized, double-blind, placebo-controlled study was to evaluate the efficacy of sustained-release methylphenidate (MPH-SR) in treatment of methamphetamine dependence. Methods: Fifty-six individuals who met DSM-IV-TR criteria for methamphetamine dependence participated in this 10-week trial. The participants were randomly allocated into two groups and received 18 to 54 mg/day sustained-released methylphenidate or placebo for 10 weeks. Craving was evaluated by a visual analogue craving scale every week. Urinary screening test for methamphetamine was carried out each week. The Beck Depression Inventory-II (BDI-II) was used to monitor participant depressive symptoms at baseline and bi-weekly during the treatment period. Results: At the end of the trial, the MPH-SR group was less methamphetamine positive compared to the placebo group and the difference was significant (p = 0.03). By the end of the study, MPH-SR group showed significantly less craving scores compared to the placebo group [MD (95% CI) = -10.28(0.88-19.18), t(54) = 2.19, p = 0.03]. There was greater improvement in the depressive symptoms scores in the intervention group compared to the placebo group [MD (95% CI) =2.03(0.31-3.75), t (54) =2.37, p = 0.02]. Conclusion: Sustained-released methylphenidate was safe and well tolerated among active methamphetamine users and significantly reduced methamphetamine use, craving and depressive symptoms. Trial registration: IRCT201202281556N38
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings
Panenka, W. J., Procyshyn, R. M., Lecomte, T., MacEwan, G. W., Flynn, S. W., Honer, W. G., & Barr, A. M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.11.016 · Cited by 432 · cited 1×
“Background Methamphetamine is a psychostimulant that is highly addictive and affects monoamine neurotransmitter systems [1].”
Hannestad, J., Gallezot, J.-D., Planeta-Wilson, B., Lin, S.-F., Williams, W. A., van Dyck, C. H., Malison, R. T., Carson, R. E., & Ding, Y.-S. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.017 · Cited by 236
Stimulant Abuse: Pharmacology, Cocaine, Methamphetamine, Treatment, Attempts at Pharmacotherapy
Ciccarone, D. (2011) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2010.11.004 · Cited by 200 · cited 2×
“consequences such as myocardial infarction, renal failure, cerebral hemorrhage, muscle damage, nasal and sinus damage and sudden death [8-12].”
Psychiatric comorbidity in methamphetamine dependence
Salo, R., Flower, K., Kielstein, A., Leamon, M. H., Nordahl, T. E., & Galloway, G. P. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2010.09.014 · Cited by 151 · cited 1×
“Methamphetamine dependence is associated with a number of psychiatric disorders including depression and psychosis [5-7].”
Heinzerling, K. G., Swanson, A.-N., Kim, S., Cederblom, L., Moe, A., Ling, W., & Shoptaw, S. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.023 · Cited by 105 · cited 2×
“Craving was evaluated by a visual analogue craving scale every week that ranges from 0 (no cravings) to 100 (most intense cravings possible) [22].”
Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: A pilot study
Konstenius, M., Jayaram-Lindström, N., Beck, O., & Franck, J. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.006 · Cited by 83 · cited 1×
“In the Konsteniusa study, sustained release methylphenidate could not affect craving for amphetamine or retention in treatment [46].”
A placebo‐controlled trial of mirtazapine for the management of methamphetamine withdrawal
CRUICKSHANK, C. C., MONTEBELLO, M. E., DYER, K. R., QUIGLEY, A., BLASZCZYK, J., TOMKINS, S., & SHAND, D. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801935672 · Cited by 74 · cited 1×
“In the last decade, many medications have been used for treatment of methamphetamine dependence including modafinil, antidepressants, ondansetron, risperidone, aripiprazole, baclofen, topiramate, N-acetyl cysteine, naltrexone, and gabapentin, but none demonstrated consistent efficacy [2,10,13,18-25].”
Miles, S. W., Sheridan, J., Russell, B., Kydd, R., Wheeler, A., Walters, C., Gamble, G., Hardley, P., Jensen, M., Kuoppasalmi, K., et al. (2013) · Addiction · doi:10.1111/add.12109 · Cited by 63
Methylphenidate vs. resperidone in treatment of methamphetamine dependence: A clinical trial
Solhi, H., Jamilian, H. R., Kazemifar, A. M., Javaheri, J., & Rasti Barzaki, A. (2014) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.04.003 · Cited by 10 · cited 1×
“Our results were in accordance with some previous studies [32,41,42].”
Cited by
Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00711-x · Cited by 194
Tardelli, V. S., Bisaga, A., Arcadepani, F. B., Gerra, G., Levin, F. R., & Fidalgo, T. M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05563-3 · Cited by 151
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
Bhatt, M., Zielinski, L., Baker-Beal, L., Bhatnagar, N., Mouravska, N., Laplante, P., Worster, A., Thabane, L., & Samaan, Z. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0370-x · Cited by 56
“value with some trials conducting as few as 10 urine tests [31].”
BackgroundMethodHärtel-Petri, R., Krampe-Scheidler, A., Braunwarth, W.-D., Havemann-Reinecke, U., Jeschke, P., Looser, W., Mühlig, S., Schäfer, I., Scherbaum, N., Bothe, L., et al. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-105500 · Cited by 39
Metadata
- Authors
- Rezaei, F., Emami, M., Zahed, S., Morabbi, M.-J., Farahzadi, M., & Akhondzadeh, S.
- Venue
- DARU Journal of Pharmaceutical Sciences
- Published
- 2015-01-15
- Volume
- 23
- Issue
- 1
- Pages
- 2-2
- ISSN
- 1560-8115 (ISSN-L)
- 2008-2231
- OpenAlex
- W2114469645
- Cited by
- 51
- References
- 9
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial. https://app.cochat.ai/papers/10.1186/s40199-015-0092-y
- The paper
- Rezaei, F., Emami, M., Zahed, S., Morabbi, M.-J., Farahzadi, M., & Akhondzadeh, S. (2015). Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial. DARU Journal of Pharmaceutical Sciences. https://doi.org/10.1186/s40199-015-0092-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.